CVRx downgraded at J.P. Morgan after Q1 sales miss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 09 2025
0mins
Should l Buy CVRX?
Source: SeekingAlpha
Stock Performance and Analyst Downgrade: CVRx shares fell after the company reported Q1 2025 sales that did not meet growth expectations, leading J.P. Morgan to downgrade the stock from Neutral to Underweight and reduce its price target significantly.
Sales Force Reorganization Impact: The decline in sales was attributed to a reorganization of the sales force, which resulted in higher turnover and account disruptions, prompting concerns about future revenue guidance and the impact of upcoming changes to payment rates under the Hospital Outpatient Prospective Payment System.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVRX
Wall Street analysts forecast CVRX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.690
Low
11.00
Averages
12.50
High
14.00
Current: 5.690
Low
11.00
Averages
12.50
High
14.00
About CVRX
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CVRx Q4 2025 Earnings Call Insights
- Revenue Growth: CVRx reported fourth-quarter revenue of $16 million and full-year revenue of $56.7 million, reflecting growth of 4% and 10% respectively, indicating the company's stable growth potential in the market.
- Market Opportunity: With 339,000 patients eligible for Barostim therapy, representing a $10.5 billion market opportunity with less than 1% penetration, the company is strategically focused on increasing its market share.
- Strategic Priorities: The company aims to build a world-class sales organization, drive deep adoption in targeted centers, and reduce barriers to adoption, having expanded to 53 territories with 252 active implanting centers, marking increases of 10% and 13% respectively.
- Financial Outlook: For 2026, total revenue is expected to range between $63 million and $67 million, with gross margins between 84% and 86%, as management expresses optimism about future growth, particularly with the new CPT code implementation reducing reimbursement friction.
See More
CVRx Reports Q4 Earnings Beat with Revenue Growth
- Earnings Report: CVRx's Q4 GAAP EPS of -$0.46 missed expectations by $0.02, indicating ongoing challenges in profitability despite revenue growth.
- Revenue Growth: The company reported $16 million in revenue, a 4.6% year-over-year increase that beat market expectations by $0.17 million, reflecting improved sales performance in the medical device sector.
- Future Outlook: At the 44th Annual J.P. Morgan Healthcare Conference, CVRx presented preliminary 2025 results and issued guidance for 2026, demonstrating confidence in future growth prospects.
- Market Reaction: Although the EPS fell short of expectations, the revenue growth and future guidance may positively influence investor sentiment, increasing market interest in CVRx.
See More
CVRx Under Investigation for Possible Securities Law Violations
- Performance Decline: On April 7, 2025, CVRx announced preliminary first-quarter results that fell short of expectations, with CEO Kevin Hykes noting that many new sales representatives are still in early development stages, leading to a share price drop from $11.54 to $6.20, a decline of 46.3%.
- Sales Team Changes: On May 8, 2025, CVRx reported weak first-quarter results again and lowered its full-year revenue guidance, with Hykes stating that 25% of territory managers were hired between December and March, indicating that the impact of sales team changes was more significant than anticipated, causing shares to fall from $7.78 to $4.77, a drop of 38.8%.
- Ongoing Legal Investigation: No lawsuit has been filed yet, but Kirby McInerney LLP is investigating potential violations of federal securities laws by CVRx and its senior management to determine if claims can be made.
- Investor Rights Protection: Investors who purchased or acquired CVRx securities or have relevant information are encouraged to contact Kirby McInerney LLP to discuss their rights and ensure they receive necessary legal support during the investigation.
See More
CVRx Faces Investor Lawsuit Investigation
- Shareholder Rights Investigation: Bragar Eagel & Squire, P.C. is investigating whether CVRx has violated federal securities laws, which could impact the company's reputation and stock price significantly.
- Performance Decline Impact: On April 7, 2025, CVRx announced weaker-than-expected preliminary first-quarter results, causing its stock price to plummet from $11.54 to $6.20, a 46.3% drop, reflecting market concerns over the development of its sales representatives.
- Sales Team Changes: During the earnings call on May 8, 2025, CEO Hykes noted that 25% of territory managers were hired in a short period, indicating significant adjustments in the sales team, which further raised investor concerns about performance.
- Call for Action: Bragar Eagel & Squire encourages affected investors to contact their attorneys to understand their legal rights, demonstrating the firm's commitment to protecting shareholder interests, which may influence the outcomes of future legal actions.
See More
CVRx Under Investigation for Potential Securities Violations
- Performance Decline: On April 7, 2025, CVRx reported weaker-than-expected preliminary Q1 results, causing shares to plummet from $11.54 to $6.20, a 46.3% drop, indicating issues with the development of new sales representatives and eroding market confidence.
- Sales Team Changes: During the earnings call on May 8, 2025, CEO Hykes disclosed that 25% of territory managers were replaced in a short period, leading to further declines in performance and shares falling from $7.78 to $4.77, a 38.8% drop, highlighting significant missteps in management's sales strategy.
- Legal Investigation Initiated: Kirby McInerney LLP is investigating whether CVRx violated federal securities laws or engaged in unlawful business practices; while no lawsuit has been filed yet, this inquiry could have profound implications for the company's future legal liabilities and financial health.
- Investor Attention: With no lawsuits currently filed, investors with information or interest in the investigation are encouraged to contact the law firm, reflecting growing concern over CVRx's future and potential legal rights.
See More
Pomerantz LLP Investigates CVRx for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether CVRx and its executives have engaged in securities fraud or other unlawful business practices, potentially leading to significant losses for investors.
- Poor Performance Impact: CVRx's preliminary first-quarter results announced on April 7, 2025, fell short of expectations, causing the stock price to plummet 46.3% to $6.20 per share the following day, reflecting market concerns over the development of the company's sales representatives.
- Sales Team Changes: On May 8, 2025, CVRx reported weak first-quarter results and lowered its full-year revenue guidance, with the CEO noting that 25% of territory managers were replaced in a short period, exacerbating market worries about the company's future performance.
- Continued Stock Decline: Following the disappointing results, CVRx's stock price fell another 38.7% to $4.77 per share on May 9, 2025, indicating a severe lack of investor confidence in the company's outlook.
See More
CVRx Q4 2025 Earnings Call Insights
- Revenue Growth: CVRx reported fourth-quarter revenue of $16 million and full-year revenue of $56.7 million, reflecting growth of 4% and 10% respectively, indicating the company's stable growth potential in the market.
- Market Opportunity: With 339,000 patients eligible for Barostim therapy, representing a $10.5 billion market opportunity with less than 1% penetration, the company is strategically focused on increasing its market share.
- Strategic Priorities: The company aims to build a world-class sales organization, drive deep adoption in targeted centers, and reduce barriers to adoption, having expanded to 53 territories with 252 active implanting centers, marking increases of 10% and 13% respectively.
- Financial Outlook: For 2026, total revenue is expected to range between $63 million and $67 million, with gross margins between 84% and 86%, as management expresses optimism about future growth, particularly with the new CPT code implementation reducing reimbursement friction.
See More
CVRx Reports Q4 Earnings Beat with Revenue Growth
- Earnings Report: CVRx's Q4 GAAP EPS of -$0.46 missed expectations by $0.02, indicating ongoing challenges in profitability despite revenue growth.
- Revenue Growth: The company reported $16 million in revenue, a 4.6% year-over-year increase that beat market expectations by $0.17 million, reflecting improved sales performance in the medical device sector.
- Future Outlook: At the 44th Annual J.P. Morgan Healthcare Conference, CVRx presented preliminary 2025 results and issued guidance for 2026, demonstrating confidence in future growth prospects.
- Market Reaction: Although the EPS fell short of expectations, the revenue growth and future guidance may positively influence investor sentiment, increasing market interest in CVRx.
See More
CVRx Under Investigation for Possible Securities Law Violations
- Performance Decline: On April 7, 2025, CVRx announced preliminary first-quarter results that fell short of expectations, with CEO Kevin Hykes noting that many new sales representatives are still in early development stages, leading to a share price drop from $11.54 to $6.20, a decline of 46.3%.
- Sales Team Changes: On May 8, 2025, CVRx reported weak first-quarter results again and lowered its full-year revenue guidance, with Hykes stating that 25% of territory managers were hired between December and March, indicating that the impact of sales team changes was more significant than anticipated, causing shares to fall from $7.78 to $4.77, a drop of 38.8%.
- Ongoing Legal Investigation: No lawsuit has been filed yet, but Kirby McInerney LLP is investigating potential violations of federal securities laws by CVRx and its senior management to determine if claims can be made.
- Investor Rights Protection: Investors who purchased or acquired CVRx securities or have relevant information are encouraged to contact Kirby McInerney LLP to discuss their rights and ensure they receive necessary legal support during the investigation.
See More
CVRx Faces Investor Lawsuit Investigation
- Shareholder Rights Investigation: Bragar Eagel & Squire, P.C. is investigating whether CVRx has violated federal securities laws, which could impact the company's reputation and stock price significantly.
- Performance Decline Impact: On April 7, 2025, CVRx announced weaker-than-expected preliminary first-quarter results, causing its stock price to plummet from $11.54 to $6.20, a 46.3% drop, reflecting market concerns over the development of its sales representatives.
- Sales Team Changes: During the earnings call on May 8, 2025, CEO Hykes noted that 25% of territory managers were hired in a short period, indicating significant adjustments in the sales team, which further raised investor concerns about performance.
- Call for Action: Bragar Eagel & Squire encourages affected investors to contact their attorneys to understand their legal rights, demonstrating the firm's commitment to protecting shareholder interests, which may influence the outcomes of future legal actions.
See More
CVRx Under Investigation for Potential Securities Violations
- Performance Decline: On April 7, 2025, CVRx reported weaker-than-expected preliminary Q1 results, causing shares to plummet from $11.54 to $6.20, a 46.3% drop, indicating issues with the development of new sales representatives and eroding market confidence.
- Sales Team Changes: During the earnings call on May 8, 2025, CEO Hykes disclosed that 25% of territory managers were replaced in a short period, leading to further declines in performance and shares falling from $7.78 to $4.77, a 38.8% drop, highlighting significant missteps in management's sales strategy.
- Legal Investigation Initiated: Kirby McInerney LLP is investigating whether CVRx violated federal securities laws or engaged in unlawful business practices; while no lawsuit has been filed yet, this inquiry could have profound implications for the company's future legal liabilities and financial health.
- Investor Attention: With no lawsuits currently filed, investors with information or interest in the investigation are encouraged to contact the law firm, reflecting growing concern over CVRx's future and potential legal rights.
See More
Pomerantz LLP Investigates CVRx for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether CVRx and its executives have engaged in securities fraud or other unlawful business practices, potentially leading to significant losses for investors.
- Poor Performance Impact: CVRx's preliminary first-quarter results announced on April 7, 2025, fell short of expectations, causing the stock price to plummet 46.3% to $6.20 per share the following day, reflecting market concerns over the development of the company's sales representatives.
- Sales Team Changes: On May 8, 2025, CVRx reported weak first-quarter results and lowered its full-year revenue guidance, with the CEO noting that 25% of territory managers were replaced in a short period, exacerbating market worries about the company's future performance.
- Continued Stock Decline: Following the disappointing results, CVRx's stock price fell another 38.7% to $4.77 per share on May 9, 2025, indicating a severe lack of investor confidence in the company's outlook.
See More
